Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Revenue of Cassava Sciences, Inc. (SAVA)
Revenue in 2023 (TTM): $
According to Cassava Sciences, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Cassava Sciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-89,423,000 | $-95,687,000 | $-97,217,000 | $-97,217,000 |
| 2022 | $-1,800 | $-1,302,800 | $-74,945,000 | $-76,246,000 | $-72,472,000 |
| 2021 | $ | $-534,000 | $-31,851,000 | $-32,385,000 | $-31,802,000 |
| 2020 | $ | $-346,000 | $-6,312,000 | $-6,334,000 | $-5,854,000 |
| 2019 | $ | $-58,000 | $-4,573,000 | $-4,631,000 | $-4,245,000 |
| 2018 | $ | $-69,000 | $-6,488,000 | $-6,557,000 | $-6,557,000 |
| 2017 | $ | $-68,000 | $-11,843,000 | $-11,911,000 | $-11,911,000 |
| 2016 | $ | $-58,000 | $-14,792,000 | $-14,850,000 | $-14,850,000 |
| 2015 | $ | $-45,000 | $-14,100,000 | $-14,145,000 | $-14,145,000 |
| 2014 | $ | $-7,306 | $-12,371,000 | $-12,386,000 | $-12,386,000 |
| 2013 | $41.12 M | $41.11 M | $31.37 M | $31.47 M | $31.54 M |
| 2012 | $10.89 M | $10.88 M | $-3,897,000 | $-3,446,000 | $-3,446,000 |
| 2011 | $11.48 M | $11.48 M | $-3,514,000 | $-2,613,000 | $-2,613,000 |
| 2010 | $16.81 M | $16.81 M | $-13,703,000 | $-12,023,000 | $-12,023,000 |
| 2009 | $20.56 M | $20.56 M | $-6,754,000 | $-4,977,000 | $-3,467,000 |
| 2008 | $63.73 M | $63.73 M | $9.16 M | $14.73 M | $15.35 M |
| 2007 | $65.98 M | $65.98 M | $10.53 M | $20.31 M | $20.31 M |
| 2006 | $53.92 M | $53.92 M | $-553,000 | $9.12 M | $6.19 M |
| 2005 | $5.08 M | $5.08 M | $-30,302,000 | $-30,670,000 | $-30,670,000 |
| 2004 | $ | $ | $-37,393,000 | $-37,776,000 | $-37,776,000 |
| 2003 | $ | $ | $ | $-21,617,000 | $-21,617,000 |
| 2002 | $114 K | $114 K | $ | $-15,925,000 | $-15,925,000 |
| 2001 | $ | $ | $-15,871,377 | $-14,336,550 | $-14,337,350 |
| 2000 | $1 | $6.16 M | $-14,146,709 | $-17,478,990 | $-17,479,790 |
| 1999 | $1 | $1.54 M | $-3,120,382 | $-4,498,785 | $-4,499,585 |